Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation

David T. Harris, M. J. Schumacher, J. LoCascio, A. Booth, J. Bard, E. A. Boyse

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Recent clinical reports have demonstrated that umbilical cord blood (CB) may be utilized as a source of transplantable hematopoietic stem cells when bone marrow is not available. However, it is not apparent that CB can be used to transplant partially HLA-matched siblings or matched, non-familial recipients. In this study the immunoreactivity of CB has been investigated within familial confines; 14 families were analyzed at the time of birth of their child and six of these families were reassessed at 6 months post-partum. In mixed lymphocyte reactions, CB was unable to significantly respond to stimulation with cells from either the mother or father. Furthermore, unlike adult peripheral blood, CB displayed depressed immune responses to alloantigen and T cell mitogen. At 6 months, the immune responses of the infant demonstrated normal development in terms of alloantigen and mitogen responses. However, at 6 months both the mother and the infant demonstrated a continued immune tolerance to one another. The data suggest that CB could be used in familial transplant situations when siblings are HLA-haploidentical if the donor/recipients are chosen based on the paternal haplotype. Furthermore, maternal bone marrow harvested during the 6 months immediately following delivery of a child also should be suitable as a stem cell graft in haploidentical situations.

Original languageEnglish (US)
Pages (from-to)63-68
Number of pages6
JournalBone Marrow Transplantation
Volume14
Issue number1
StatePublished - 1994

Fingerprint

Fetal Blood
Transplantation
Mothers
Isoantigens
Transplants
Mitogens
Siblings
Stem Cells
Bone Marrow
Immune Tolerance
Mixed Lymphocyte Culture Test
Hematopoietic Stem Cells
Fathers
Haplotypes
Tissue Donors
Parturition
T-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation. / Harris, David T.; Schumacher, M. J.; LoCascio, J.; Booth, A.; Bard, J.; Boyse, E. A.

In: Bone Marrow Transplantation, Vol. 14, No. 1, 1994, p. 63-68.

Research output: Contribution to journalArticle

Harris, David T. ; Schumacher, M. J. ; LoCascio, J. ; Booth, A. ; Bard, J. ; Boyse, E. A. / Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation. In: Bone Marrow Transplantation. 1994 ; Vol. 14, No. 1. pp. 63-68.
@article{79f1ee5902524abc9e6c8b7fc7f61922,
title = "Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation",
abstract = "Recent clinical reports have demonstrated that umbilical cord blood (CB) may be utilized as a source of transplantable hematopoietic stem cells when bone marrow is not available. However, it is not apparent that CB can be used to transplant partially HLA-matched siblings or matched, non-familial recipients. In this study the immunoreactivity of CB has been investigated within familial confines; 14 families were analyzed at the time of birth of their child and six of these families were reassessed at 6 months post-partum. In mixed lymphocyte reactions, CB was unable to significantly respond to stimulation with cells from either the mother or father. Furthermore, unlike adult peripheral blood, CB displayed depressed immune responses to alloantigen and T cell mitogen. At 6 months, the immune responses of the infant demonstrated normal development in terms of alloantigen and mitogen responses. However, at 6 months both the mother and the infant demonstrated a continued immune tolerance to one another. The data suggest that CB could be used in familial transplant situations when siblings are HLA-haploidentical if the donor/recipients are chosen based on the paternal haplotype. Furthermore, maternal bone marrow harvested during the 6 months immediately following delivery of a child also should be suitable as a stem cell graft in haploidentical situations.",
author = "Harris, {David T.} and Schumacher, {M. J.} and J. LoCascio and A. Booth and J. Bard and Boyse, {E. A.}",
year = "1994",
language = "English (US)",
volume = "14",
pages = "63--68",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation

AU - Harris, David T.

AU - Schumacher, M. J.

AU - LoCascio, J.

AU - Booth, A.

AU - Bard, J.

AU - Boyse, E. A.

PY - 1994

Y1 - 1994

N2 - Recent clinical reports have demonstrated that umbilical cord blood (CB) may be utilized as a source of transplantable hematopoietic stem cells when bone marrow is not available. However, it is not apparent that CB can be used to transplant partially HLA-matched siblings or matched, non-familial recipients. In this study the immunoreactivity of CB has been investigated within familial confines; 14 families were analyzed at the time of birth of their child and six of these families were reassessed at 6 months post-partum. In mixed lymphocyte reactions, CB was unable to significantly respond to stimulation with cells from either the mother or father. Furthermore, unlike adult peripheral blood, CB displayed depressed immune responses to alloantigen and T cell mitogen. At 6 months, the immune responses of the infant demonstrated normal development in terms of alloantigen and mitogen responses. However, at 6 months both the mother and the infant demonstrated a continued immune tolerance to one another. The data suggest that CB could be used in familial transplant situations when siblings are HLA-haploidentical if the donor/recipients are chosen based on the paternal haplotype. Furthermore, maternal bone marrow harvested during the 6 months immediately following delivery of a child also should be suitable as a stem cell graft in haploidentical situations.

AB - Recent clinical reports have demonstrated that umbilical cord blood (CB) may be utilized as a source of transplantable hematopoietic stem cells when bone marrow is not available. However, it is not apparent that CB can be used to transplant partially HLA-matched siblings or matched, non-familial recipients. In this study the immunoreactivity of CB has been investigated within familial confines; 14 families were analyzed at the time of birth of their child and six of these families were reassessed at 6 months post-partum. In mixed lymphocyte reactions, CB was unable to significantly respond to stimulation with cells from either the mother or father. Furthermore, unlike adult peripheral blood, CB displayed depressed immune responses to alloantigen and T cell mitogen. At 6 months, the immune responses of the infant demonstrated normal development in terms of alloantigen and mitogen responses. However, at 6 months both the mother and the infant demonstrated a continued immune tolerance to one another. The data suggest that CB could be used in familial transplant situations when siblings are HLA-haploidentical if the donor/recipients are chosen based on the paternal haplotype. Furthermore, maternal bone marrow harvested during the 6 months immediately following delivery of a child also should be suitable as a stem cell graft in haploidentical situations.

UR - http://www.scopus.com/inward/record.url?scp=0028237520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028237520&partnerID=8YFLogxK

M3 - Article

C2 - 7951121

AN - SCOPUS:0028237520

VL - 14

SP - 63

EP - 68

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -